Preferred Label : Allogeneic Autophagosome-enriched Vaccine DPV-001;
NCIt synonyms : Dribbles Vaccine DPV-001; DRiPs and SLiPs-containing Blebs Vaccine DPV-001; Dribble Cancer Vaccine DPV-001; Tumor-derived Autophagosomes Vaccine DPV-001; DPV-001 Vaccine; Vaccine DPV-001; Allogeneic DRibble Vaccine DPV-001; DRibble Vaccine DPV-001;
NCIt definition : An off-the-shelf (OTS) autophagosome-enriched tumor vaccine composed of dendritic
cell (DC)-targeting microvesicles containing short lived proteins (SLiPs) and defective
ribosomal products (DRiPs) derived from tumor cells, with potential immunostimulating
and antineoplastic activities. The DriPs- and SLiPs-filled autophagosome microvesicles
are made by treating two human non-small cell lung cancer (NSCLC) cell lines, UbiLT3
(non-specific histopathology) and UbiLT6 (adenocarcinoma-like) with both a proteasome
inhibitor, to prevent protein degradation, and an autophagy inducer. DPV-001 contains
a wide variety of NSCLC-derived TAAs, many as immunogenic altered-peptide ligands
(APL), and numerous damage-associated molecular pattern molecules (DAMPs) with Toll-like
receptor (TLR) 2, 3, 4, 7 and 9 agonist activities. Upon administration of allogeneic
autophagosome-enriched vaccine DPV-001, the proteins in the vaccine target DCs and
may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte
responses against the TAAs. The TAAs are overexpressed in a variety of cancer cell
types other than NSCLC. The tumor-associated SLiPS and DRiPs are highly unstable and
normally degraded by tumor cell proteasomes. They are typically not processed and
cross-presented by antigen-presenting cells (APCs).;
Molecule name : DPV 001; DPV-001;
NCI Metathesaurus CUI : CL451870;
Origin ID : C107681;
UMLS CUI : C5417778;
Semantic type(s)
- concept_is_in_subset
